Merck & Co., Inc. (NYSE:MRK) on Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background ...
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Merck (NYSE:MRK) with a Peer Perform recommendation. As of October 21, 2024, the average one-year price target for Merck ...
As of September 24, 2024, the average one-year price target for Merck is $142.74/share. The forecasts range from a low of $126.25 to a high of $162.75. The average price target represents an increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback